@article{ref1,
title="A phase 1b, double blind, randomized study of cannabis oil for pain in Parkinson's disease",
journal="Movement disorders clinical practice",
year="2023",
author="Di Luca, D.G. and Gilmour, G.S. and Fearon, C. and Swinkin, E. and Freitas, E. and Kuhlman, G. and Fox, S.H. and Mestre, T.",
volume="10",
number="7",
pages="1114-1119",
abstract="BACKGROUND: Pain is common in Parkinson's disease (PD), but effective therapies are limited. <br><br>OBJECTIVES: To determine the maximum tolerated dose (MTD) and safety of formulations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) for pain in PD. <br><br>METHODS: In this phase 1b, double-blind, randomized, single-center study, participants were randomized to three formulations of THC/CBD (18:0, 10:10, and 1:20). The MTD, adverse events (AE), and tolerability are described for each formulation. <br><br>RESULTS: Eight participants were randomized. The MTD was similar among groups (0.8-0.9 mL/daily), and there were no serious AE or study drop-outs. The most common AE were drowsiness and dizziness (three participants). Epworth sleepiness scale scores were higher in the high CBD formulation (1:20). <br><br>CONCLUSIONS: In patients with pain and PD, mixed formulations of THC/CBD were tolerated with no serious AE. Considering the safety profile, future phase II studies should be considered. © 2023 International Parkinson and Movement Disorder Society.<p /> <p>Language: en</p>",
language="en",
issn="2330-1619",
doi="10.1002/mdc3.13754",
url="http://dx.doi.org/10.1002/mdc3.13754"
}